Press Releases

May 26, 2020
BOSTON , May 26, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper , President and Chief Executive Officer, will present via webcast at the 2020 Jefferies
May 7, 2020
— Commercial preparations advancing, with topline PEDFIC 1 results expected mid-2020  — — First sites initiated for second pivotal trial in biliary atresia — — Management to host conference call and webcast today at 10:00 a.m. ET — BOSTON , May 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.
April 30, 2020
Conference call and webcast to be held at 10:00 a.m. ET BOSTON , April 30, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that management will host a conference call and
April 7, 2020
BOSTON , April 07, 2020 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford , Chief Financial Officer, will present via webcast at the 19th Annual Needham